Form 4: Elanco CEO Jeffrey Simmons Files Future Acquisition of Deferred Stock Units

Elanco Animal Health Inc.'s President, CEO, and Director, Jeffrey N. Simmons, has filed a Form 4 indicating a future acquisition of 185.855 deferred stock units on July 11, 2025, under a pre-arranged plan.

Summary

• Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc. (ELAN), is set to acquire 185.855 Deferred Stock Units (DSUs).
• The transaction date for this acquisition is July 11, 2025.
• Each DSU represents the right to receive one share of Company common stock or its cash equivalent.
• The DSUs were acquired at a price of $14.9 per unit.
• Following this transaction, Jeffrey N. Simmons will beneficially own a total of 17,035.3066 Deferred Stock Units.
• The acquisition is made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• DSUs settle in cash or shares of Company common stock upon termination of employment or during a specified future year, in accordance with the Executive Deferral and Stock Match Plan.

Sentiment

Score: 7

Explanation: The acquisition of additional deferred stock units by the CEO, even if part of a compensation plan, generally signals confidence and aligns management's interests with shareholders. The pre-planned nature (Rule 10b5-1) makes it a neutral-to-positive event, as opposed to a spontaneous open-market purchase, but still reflects ongoing equity participation.

Positives

• Acquisition of additional deferred stock units by the CEO indicates continued alignment of management's interests with shareholders.
• The transaction is part of a pre-arranged plan (Rule 10b5-1(c)), suggesting a structured and compliant approach to executive compensation and ownership.

Risks

• The value of the deferred stock units is tied to the future performance of Elanco's common stock, exposing the holder to market fluctuations.
• Settlement of DSUs is contingent on future events (termination of employment or specified future year), introducing a time-based risk for liquidity.

Future Outlook

The acquisition of deferred stock units on a future date (July 11, 2025) indicates a pre-planned compensation or ownership increase for the CEO, aligning his future interests with the company's performance. The units will settle upon termination of employment or a specified future year.

Industry Context

This transaction is specific to Elanco Animal Health Inc. and its executive compensation structure. It does not provide broader industry trends or competitive analysis, but it is common for executives in the animal health sector, like other industries, to receive equity-based compensation.

Corporate Governance

Related Party Transactions

• Acquisition of 185.855 Deferred Stock Units by Jeffrey N. Simmons, the President, CEO, and Director of Elanco Animal Health Inc., from the company. This is an insider transaction.

Stakeholder Impact

• Shareholders: May view the CEO's increased equity ownership as a positive sign of alignment with shareholder interests and confidence in the company's future.

Next Steps

• Settlement of the deferred stock units in cash or shares of common stock upon termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Key Dates

Keywords

Elanco Animal Health, ELAN, Jeffrey N. Simmons, Deferred Stock Units, DSU, Insider Transaction, SEC Form 4, Executive Compensation, Rule 10b5-1, Animal Health